Evidence map›Paper›PMID 38244864›Full record

ArticlePharmacology, biochemistry, and behavior2024

Somatic and anxiety-like behaviors in male and female rats during withdrawal from the non-selective cannabinoid agonist WIN 55,212-2.

Abigail L Brewer, Claire E Felter, Anna R Sternitzky, Sade M Spencer

Open access · greenAbstract read
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Abigail L BrewerDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, United States of America; Medical Discovery Team on Addiction, University of Minnesota, Minneapolis, MN, United States of America. Electronic address: Brewe063@umn.edu.
Claire E FelterDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, United States of America; Medical Discovery Team on Addiction, University of Minnesota, Minneapolis, MN, United States of America.
Anna R SternitzkyDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, United States of America; Medical Discovery Team on Addiction, University of Minnesota, Minneapolis, MN, United States of America.
Sade M SpencerDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, United States of America; Medical Discovery Team on Addiction, University of Minnesota, Minneapolis, MN, United States of America.
University of Minnesota · US

Funding

Viral Innovation CoreP30DA048742 · NIDA · UNIVERSITY OF MINNESOTA · PI Mark John Thomas · 2020 to 2026
$19.0M
NEUROSCIENCE TRAINING IN DRUG ABUSE RESEARCHT32DA007234 · NIDA · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Paul G Mermelstein, Jocelyn M Richard · 1986 to 2026
$10.9M
NIDA NIH HHS P30 DA048742NIDA NIH HHS T32 DA007234
6 · The paper itself

Abstract

Synthetic cannabinoids are associated with higher risk of dependence and more intense withdrawal symptoms than plant-derived Δ9-tetrahydrocannabinol (THC). Avoidance of withdrawal symptoms, including anxiogenic effects, can contribute to continued cannabinoid use. Adult male and female Long-Evans rats were given escalating doses of WIN 55,212-2 (WIN) via twice daily intrajugular infusions. Precipitated withdrawal was elicited with SR 141716 (rimonabant) 4 h after the final infusion. Global withdrawal scores (GWS) were compiled by summing z-scores of observed somatic behaviors over a 30-min period with locomotor activity simultaneously collected via beam breaks. Rimonabant precipitated withdrawal in female and male rats at 3 or 10 mg/kg, respectively, but the individual behaviors contributing to GWS were not identical. 3 mg/kg rimonabant did not impact locomotor behavior in females, but 10 mg/kg decreased locomotion in male controls. Spontaneous withdrawal observed between 6 and 96 h after the final infusion was quantifiable up to 24 h following WIN administration. Individual behaviors contributing to GWS varied by sex and time point. Males undergoing spontaneous withdrawal engaged in more locomotion than females undergoing withdrawal. Separate groups of rats were subjected to a battery of anxiety-like behavioral tests (elevated plus maze, open field test, and marble burying test) one or two weeks after WIN or vehicle infusions. At one week abstinence, sex-related effects were noted in marble burying and the open field test but were unrelated to drug treatment. At two weeks abstinence, females undergoing withdrawal spent more time grooming during marble burying and performed more marble manipulations than their male counterparts. WIN infusions did not impact estrous cycling, and GWS scores were not correlated with estrous at withdrawal. Collectively, these results show qualitative sex differences in behaviors contributing to the behavioral experience of cannabinoid withdrawal supporting clinical findings from THC.

Indexed as

BenzoxazinesCannabinoidsMorpholinesNaphthalenesSubstance Withdrawal SyndromeAnimalsAnxietyCalcium CarbonateCannabinoid Receptor AgonistsDronabinolFemaleMalePiperidinesPyrazolesRatsRats, Long-Evans(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneBenzoxazinesCalcium CarbonateCannabinoid Receptor AgonistsCannabinoidsDronabinolMorpholinesNaphthalenesPiperidinesPyrazolesRimonabantAnxiety-like behaviorsCannabinoid withdrawalRodent models of withdrawalSex differencesSynthetic cannabinoid

Identifiers

PMID38244864
PMCPMC10923112
OpenAlexW4390972496

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.